EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease

Rohit Loomba iD, Ginger Clark, Jeff Teckman, Veeral Ajmera iD, Cynthia Behling, Mark Brantly, David Brenner, Jeanine D'Armiento, Michael W Fried, Janani S Iyer, Mattias Mandorfer iD, Don C Rockey iD und 6 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17967 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Rohit Loomba und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Biomarkers, Drug Development, Liver Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Novo Nordisk, Resoundant, Inc., Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alpha‐1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha‐1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non‐invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD.

Aims

To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments.

Methods

This report was developed following a multi‐stakeholder forum organised by the Alpha‐1 Antitrypsin Deficiency Related Liver Disease Expert Panel in which experts presented an overview of the available literature on this topic.

Results

AATLD results from a ‘gain of toxic function’ and primarily manifests in those with the homozygous Pi*ZZ genotype. Accumulation of misfolded ‘Z’ AAT protein in liver cells triggers intracellular hepatocyte injury which may ultimately lead to hepatic fibrosis. Male gender, age over 50 years, persistently elevated liver tests, concomitant hepatitis B or C virus infection, and metabolic syndrome, including obesity and type 2 diabetes mellitus, are known risk factors for adult AATLD. While the gold standard for assessing AATLD disease activity is liver histology, less invasive measures with low intra‐ and inter‐observer variability are needed. Measurement of liver stiffness shows promise; validated thresholds for staging AATLD are in development. Such advances will help patients by enabling risk stratification and personalised surveillance, along with streamlining the development process for novel therapies.

Conclusions

This inaugural forum generated a list of recommendations to address unmet needs in the field of AATLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin DeficiencyBiomarkersDrug DevelopmentLiver DiseasesHumansalpha 1-AntitrypsinRisk FactorsDisease Progression

Substanzen

Biomarkersalpha 1-Antitrypsin

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, San Diego, California, USA.
  • Department of Medicine, University of Florida, Gainesville, Florida, USA.
  • Pediatrics and Biochemistry, St. Louis University School of Medicine, Saint Louis, Missouri, USA.
  • Pacific Rim Pathology Lab, San Diego, California, USA.
  • Division of Pulmonary, Critical Care & Sleep Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.

ORCID-Profile: Rohit Loomba, Veeral Ajmera, Mattias Mandorfer, Don C Rockey, Monica Tincopa, Raj Vuppalanchi, Zobair Younossi, Aleksander Krag, Pavel Strnad

Förderung

  • Novo Nordisk
  • Resoundant, Inc.
  • Takeda Pharmaceutical Company

Zitieren

APA

Loomba, R., Clark, G., Teckman, J., Ajmera, V., Behling, C., Brantly, M., Brenner, D., D'Armiento, J., Fried, M. W., Iyer, J. S., Mandorfer, M., Rockey, D. C., Tincopa, M., Vuppalanchi, R., Younossi, Z., Krag, A., Turner, A. M., & Strnad, P. (2024). Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17967

Vancouver

Loomba R, Clark G, Teckman J, Ajmera V, Behling C, Brantly M, et al. Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17967

BibTeX
@article{Loomba2024,
  author = {Loomba, Rohit and Clark, Ginger and Teckman, Jeff and Ajmera, Veeral and Behling, Cynthia and Brantly, Mark and Brenner, David and D'Armiento, Jeanine and Fried, Michael W and Iyer, Janani S and Mandorfer, Mattias and Rockey, Don C and Tincopa, Monica and Vuppalanchi, Raj and Younossi, Zobair and Krag, Aleksander and Turner, Alice M and Strnad, Pavel},
  title = {Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17967}
}
Kostenlos starten →